UTA2-1 peptide-loaded PD-L silenced donor dendritic cells

UTA2-1 peptide-loaded PD-L silenced donor dendritic cells is an investigational cell-based immunotherapy developed by VU University Medical Center and Radboud University Medical Center. The therapy consists of donor-derived monocyte-derived dendritic cells (moDCs) that are engineered using siRNA to silence the immune checkpoint ligands PD-L1 and PD-L2 and are subsequently loaded with the minor histocompatibility antigen (MiHA) UTA2-1 peptide. This approach is designed to enhance the priming and expansion of UTA2-1-specific donor CD8+ T cells by preventing PD-1-mediated inhibitory signaling during antigen presentation. The primary goal is to boost graft-versus-tumor (GVT) immunity in patients with hematologic malignancies, such as multiple myeloma and acute myeloid leukemia, who have undergone allogeneic stem cell transplantation.

Other names

PD-L silenced UTA2-1 peptide-loaded dendritic cellsUTA2-1 peptide-loaded PD-L1/L2 silenced donor dendritic cells